Literature DB >> 18830229

Missense mutations to the TSC1 gene cause tuberous sclerosis complex.

Mark Nellist1, Diana van den Heuvel, Diane Schluep, Carla Exalto, Miriam Goedbloed, Anneke Maat-Kievit, Ton van Essen, Karin van Spaendonck-Zwarts, Floor Jansen, Paula Helderman, Gabriella Bartalini, Outi Vierimaa, Maila Penttinen, Jenneke van den Ende, Ans van den Ouweland, Dicky Halley.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in a variety of organs and tissues. The disease is caused by mutations in either the TSC1 gene on chromosome 9q34 or the TSC2 gene on chromosome 16p13.3. The TSC1 and TSC2 gene products, TSC1 and TSC2, interact to form a protein complex that inhibits signal transduction to the downstream effectors of the mammalian target of rapamycin (mTOR). Here we investigate the effects of putative TSC1 missense mutations identified in individuals with signs and/or symptoms of TSC on TSC1-TSC2 complex formation and mTOR signalling. We show that specific amino-acid substitutions close to the N-terminal of TSC1 reduce steady-state levels of TSC1, resulting in the activation of mTOR signalling and leading to the symptoms of TSC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830229      PMCID: PMC2986174          DOI: 10.1038/ejhg.2008.170

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  26 in total

1.  Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.

Authors:  Y Niida; N Lawrence-Smith; A Banwell; E Hammer; J Lewis; R L Beauchamp; K Sims; V Ramesh; L Ozelius
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

2.  TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.

Authors:  M Nellist; B Verhaaf; M A Goedbloed; A J Reuser; A M van den Ouweland; D J Halley
Journal:  Hum Mol Genet       Date:  2001-12-01       Impact factor: 6.150

3.  Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.

Authors:  A K Hodges; S Li; J Maynard; L Parry; R Braverman; J P Cheadle; J E DeClue; J R Sampson
Journal:  Hum Mol Genet       Date:  2001-12-01       Impact factor: 6.150

4.  Analysis of TSC2 stop codon variants found in tuberous sclerosis patients.

Authors:  M A Goedbloed; M Nellist; B Verhaaf; A J Reuser; D Lindhout; L Sunde; S Verhoef; D J Halley; A M van den Ouweland
Journal:  Eur J Hum Genet       Date:  2001-11       Impact factor: 4.246

5.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

6.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

7.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

8.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Authors:  Anja Jaeschke; Joerg Hartkamp; Masao Saitoh; Wendy Roworth; Takahiro Nobukuni; Angela Hodges; Julian Sampson; George Thomas; Richard Lamb
Journal:  J Cell Biol       Date:  2002-10-28       Impact factor: 10.539

10.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

View more
  8 in total

1.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

Review 2.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Authors:  Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

3.  Genotype and cognitive phenotype of patients with tuberous sclerosis complex.

Authors:  Agnies M van Eeghen; Margaux E Black; Margaret B Pulsifer; David J Kwiatkowski; Elizabeth A Thiele
Journal:  Eur J Hum Genet       Date:  2011-12-21       Impact factor: 4.246

4.  Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence.

Authors:  Elaine A Dunlop; Kayleigh M Dodd; Stephen C Land; Peter A Davies; Nicole Martins; Helen Stuart; Shane McKee; Chris Kingswood; Anand Saggar; Isabel Corderio; Ana Maria Duarte Medeira; Helen Kingston; Julian R Sampson; David Mark Davies; Andrew R Tee
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

Review 5.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

6.  Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex.

Authors:  Melika Mozaffari; Marianne Hoogeveen-Westerveld; David Kwiatkowski; Julian Sampson; Rosemary Ekong; Sue Povey; Johan T den Dunnen; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  BMC Med Genet       Date:  2009-09-11       Impact factor: 2.103

Review 7.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

8.  Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.

Authors:  Socratis Avgeris; Florentia Fostira; Andromachi Vagena; Yiannis Ninios; Angeliki Delimitsou; Radek Vodicka; Radek Vrtel; Sotirios Youroukos; Dimitrios J Stravopodis; Metaxia Vlassi; Aristotelis Astrinidis; Drakoulis Yannoukakos; Gerassimos E Voutsinas
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.